Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MPI | P34949 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7591613 | 0.77 | CYP2C9 (0.55) | CYP2C9MAPTLMNAALDH1A1KDM4E | |
| SCHEMBL239326 | 0.77 | CYP2C9 (0.59) | CYP2C9MAPTLMNAALDH1A1KDM4E | |
| SCHEMBL239325 | 0.77 | CYP2C9 (0.59) | CYP2C9MAPTLMNAALDH1A1KDM4E | |
| SCHEMBL29472028 | 0.77 | CYP2C9 (0.59) | CYP2C9MAPTLMNAALDH1A1KDM4E | |
| SCHEMBL22617845 | 0.76 | ATM (0.38) | CYP2C9MAPTALDH1A1KDM4ERECQL | |
| SCHEMBL9336284 | 0.75 | CYP2C9 (0.57) | CYP2C9MAPTLMNAALDH1A1KDM4E | |
| SCHEMBL12459466 | 0.75 | CYP2C9 (0.57) | CYP2C9MAPTLMNAALDH1A1KDM4E | |
| SCHEMBL22539007 | 0.75 | CYP2C9 (0.57) | CYP2C9MAPTLMNAALDH1A1KDM4E | |
| SCHEMBL12332461 | 0.74 | CYP2C9 (0.52) | CYP2C9MAPTLMNAALDH1A1KDM4E | |
| SCHEMBL6451652 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242556-A1 | NOVEL METHOD FOR MANUFACTURING DEUTERATED BORON COMPOUND | SFC CO., LTD. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230140397-A1 | ANTI-PSMA ANTIBODY-EXATECAN ANALOGUE CONJUGATE AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| WO-2022135555-A1 | PURINONE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 江苏恒瑞医药股份有限公司 | 2022-06-30 | — | — | WO | disclosed |
| EP-3017488-B1 | OPTOELECTRONIC DEVICE AND METHOD FOR PRODUCING AN OPTOELECTRONIC DEVICE | OSRAM OLED GMBH (DE) | 2020-08-19 | — | — | EP | disclosed |
| US-10647695-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-10251880-B2 | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions | SATIOGEN PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20190038611-A1 | Novel CYP34A-Specific Inhibitors and Methods of Using Same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-02-07 | — | — | US | disclosed |
| US-10166214-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2019-01-01 | — | — | US | disclosed |
| US-10038143-B2 | Polymer compound, material for electronic elements, material for organic electroluminescent elements, and organic electroluminescent element | IDEMITSU KOSAN CO., LTD. (JP) | 2018-07-31 | — | — | US | disclosed |
| US-20180092880-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2018-04-05 | — | — | US | disclosed |
| US-9868108-B2 | Specific sorbent for binding proteins and peptides, and separation method using the same | INSTRACTION GMBH (DE) | 2018-01-16 | — | — | US | disclosed |
| EP-2997021-B1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | CENTREXION THERAPEUTICS CORP (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170106349-A1 | SPECIFIC SORBENT FOR BINDING PROTEINS AND PEPTIDES, AND SEPARATION METHOD USING THE SAME | INSTRACTION GMBH (DE) | 2017-04-20 | — | — | US | disclosed |
| US-9234056-B2 | Polymerizable compound, polymerizable composition, polymer, and optically anisotropic body | ZEON CORPORATION (JP) | 2016-01-12 | — | — | US | disclosed |
| US-9207362-B2 | Copolymer, optically anisotropic substance, and oriented polymer film | ZEON CORPORATION (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2910579-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC SUBSTANCE | Zeon Corporation (JP) | 2015-08-26 | — | — | EP | disclosed |
| EP-2910986-A1 | RETARDER, CIRCULARLY POLARISING PLATE, AND IMAGE DISPLAY DEVICE | Zeon Corporation (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-20150232625-A1 | COPOLYMER, OPTICALLY ANISOTROPIC SUBSTANCE, AND ORIENTED POLYMER FILM | ZEON CORPORATION (JP) | 2015-08-20 | — | — | US | disclosed |
| EP-2871192-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC BODY, AND METHOD FOR PRODUCING POLYMERIZABLE COMPOUND | Zeon Corporation (JP) | 2015-05-13 | — | — | EP | disclosed |
| US-20140107247-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC BODY | ZEON CORPORATION (JP) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251880-B2 | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions | SLC10A2, GPR119, GPBAR1 | CYP2C9 3391/4885MAPT 2862/4885LMNA 4867/4885 |
| US-10647695-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | CYP2C9 446/4885MAPT 694/4885LMNA 419/4885 |
| US-20180092880-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR3, SSTR1 | CYP2C9 3140/4885MAPT 4338/4885LMNA 4510/4885 |
| US-20230140397-A1 | ANTI-PSMA ANTIBODY-EXATECAN ANALOGUE CONJUGATE AND MEDICAL USE THEREOF | FOLH1, ENPEP, PEPD | CYP2C9 1766/4885MAPT 861/4885LMNA 1080/4885 |
| US-20230242556-A1 | NOVEL METHOD FOR MANUFACTURING DEUTERATED BORON COMPOUND | BCL6B, BRD7, DBF4 | CYP2C9 2068/4885MAPT 1321/4885LMNA 1747/4885 |
| US-20190038611-A1 | Novel CYP34A-Specific Inhibitors and Methods of Using Same | CYP3A43, CYP3A4, CYP4B1 | CYP2C9 27/4885MAPT 3916/4885LMNA 4628/4885 |
| US-20140107247-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICALLY ANISOTROPIC BODY | H1-0, H1-2, H1-4 | CYP2C9 1192/4885MAPT 320/4885LMNA 231/4885 |
| US-10166214-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR3, SSTR1 | CYP2C9 3140/4885MAPT 4338/4885LMNA 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.